ArticleDiscover oncology2025
Combination of RNA-sequencing data analysis, network pharmacology, molecular docking techniques to investigate the mechanism of Prunella vulgaris L. in the treatment of non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Discovery of Potential Repellent Compounds forInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrunella vulgaris L. (PVL) extracts have been reported to inhibit the proliferation and promote the apoptosis of lung cancer cells. However, its pharmacological mechanism remains unclear. The objective of this study was to explore the main active ingredients and potential molecular mechanisms of PVL in the treatment of non-small cell lung cancer (NSCLC). MATERIALS AND
methodsThe differentially expressed genes (DEGs) associated with NSCLC were obtained by analyzing microarray dataset GSE136043 in Gene Expression Omnibus. The bioactive components of PVL were obtained using TCMSP database, and the related targets of PVL were collected using the Swiss Target Prediction database, and drug-disease common targets were subsequently obtained. Protein-protein interaction (PPI) network was constructed using a STRING database and core targets were obtained via Cytoscape 3.9.0 software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the common targets were performed using DAVID database. Molecular docking analysis was then performed using AutoDock Vina software. Finally, the therapeutic activity of morin, a crucial component of PVL, against NSCLC was verified by in vitro experiments.
resultsA total of 11 active components and 180 targets of PVL were obtained, 39 of which overlapped with NSCLC's disease targets, and were considered to be "drug-disease" common targets. Morin, luteolin, delphinidin, kaempferol and quercetin were considered key components of PVL in NSCLC treatment. AKT1, MMP9, ESR1, XDH, MAPT, and CYP1B1 were considered to be the core targets in the PPI network. These "drug-disease" common targets were associated with 100 GO items, including 41 biological processes, 16 cellular components, and 43 molecular functions. KEGG enrichment analysis identified 14 signaling pathways. The key components morin, luteolin, delphinidin, kaempferol and quercetin had good binding affinity with the core targets (AKT1, MMP9, ESR1, XDH and CYP1B1). Additionally, morin could inhibit NSCLC cell viability and promote cell apoptosis in a dose-dependent manner. In addition, morin could also reduce mRNA expression levels of core targets.
conclusionPVL may have the potential to treat NSCLC with a multi-component, multi-target and multi-pathway manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.